Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
HIV-1 Gag-derived p24 and Pol-derived RT epitopes are peptide fragments obtained from the HIV-1 capsid protein (p24, encoded by the gag gene) and the HIV-1 reverse transcriptase enzyme (encoded by the pol gene). These epitopes are used extensively in immunological research, especially to study virus-specific T cell responses in infected individuals or in vaccine trials, due to their conservation among HIV-1 variants and their importance in the viral life cycle. While p24 and RT are the targets of drug intervention and play structural and enzymatic roles within the virus, their epitopes serve as dominant targets for T cell-mediated immunity. However, the term as used here does not refer to a specific, single molecular target but rather to a collection of antigenic peptides utilized for immune monitoring and vaccine development.
Not applicable to the epitopes themselves. As epitopes: They are recognized by cytotoxic T lymphocytes (CTLs) during immune surveillance, with their presentation on MHC class I molecules leading to CTL activation and potential killing of infected cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on HIV-1 Gag-derived p24 epitopes and Pol-derived reverse transcriptase epitopes (p24, RT).